Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CLSD Clearside Biomedical Inc
- Stocks
- Healthcare
- NASDAQ: CLSD
Price (delayed)
$0.76
Market cap
$59.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.41
Enterprise value
$99.49M
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS
Highlights
The EPS has grown by 25% year-on-year and by 13% since the previous quarter
The company's net income rose by 12% YoY and by 10% QoQ
CLSD's equity has dropped by 110% year-on-year and by 18% since the previous quarter
The company's gross profit has shrunk by 87% YoY and by 32% QoQ
Key stats
What are the main financial stats of CLSD
Market
Valuations
Earnings
Shares outstanding
77.71M
Market cap
$59.06M
Enterprise value
$99.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
40.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.38
Revenue
$1.43M
Gross profit
$1.04M
Operating income
-$28.21M
Net income
-$30.81M
EBIT
-$30.1M
EBITDA
-$29.81M
Free cash flow
-$23.61M
Per share
Balance sheet
Liquidity
EPS
-$0.41
EPS diluted
-$0.41
Free cash flow per share
-$0.31
Book value per share
-$0.6
Revenue per share
$0.02
TBVPS
$0.26
Total assets
$19.67M
Total liabilities
$65.58M
Debt
$54.06M
Equity
-$45.91M
Working capital
$10.95M
Debt to equity
-1.18
Current ratio
3.19
Quick ratio
3.03
Net debt/EBITDA
-1.36
Margins
Efficiency
Dividend
EBITDA margin
-2,079%
Gross margin
72.3%
Net margin
-2,148.6%
Operating margin
-1,967.1%
Return on assets
-114.2%
Return on equity
N/A
Return on invested capital
-53.5%
Return on capital employed
-205.3%
Return on sales
-2,098.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLSD stock price
How has the Clearside Biomedical stock price performed over time
Intraday
3.4%
1 week
-3.38%
1 month
-12.61%
1 year
-39.68%
YTD
-20%
QTD
-17.2%
Financial performance
How have Clearside Biomedical's revenue and profit performed over time
Revenue
$1.43M
Gross profit
$1.04M
Operating income
-$28.21M
Net income
-$30.81M
Gross margin
72.3%
Net margin
-2,148.6%
The company's gross profit has shrunk by 87% YoY and by 32% QoQ
The revenue has plunged by 83% YoY and by 14% from the previous quarter
CLSD's gross margin is down by 24% YoY and by 21% from the previous quarter
The operating margin is down by 13% from the previous quarter
Price vs fundamentals
How does CLSD's price correlate with its fundamentals
Growth
What is Clearside Biomedical's growth rate over time
Valuation
What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
N/A
P/S
40.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.38
The EPS has grown by 25% year-on-year and by 13% since the previous quarter
CLSD's equity has dropped by 110% year-on-year and by 18% since the previous quarter
The revenue has plunged by 83% YoY and by 14% from the previous quarter
The P/S is 39% above the 5-year quarterly average of 28.4 and 34% above the last 4 quarters average of 29.4
Efficiency
How efficient is Clearside Biomedical business performance
Clearside Biomedical's return on invested capital has increased by 37% YoY and by 17% QoQ
The company's return on assets fell by 21% YoY and by 7% QoQ
Dividends
What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLSD.
Financial health
How did Clearside Biomedical financials performed over time
The company's total assets is 70% lower than its total liabilities
The company's total assets has shrunk by 51% YoY and by 22% QoQ
CLSD's quick ratio is down by 49% YoY and by 29% from the previous quarter
CLSD's equity has dropped by 110% year-on-year and by 18% since the previous quarter
The debt to equity has grown by 43% YoY and by 13% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.